Caution should be exercised when anticoagulants are given in concomitant with Fenofibrate. The dosage of the anticoagulants should be reduced to maintain the prothrombin time at the normal level to prevent bleeding complications. Prothrombin time monitoring is advisable until it has been determined that the prothrombin time has stabilized at normal levels. In concurrent therapy with resin, it is recommended to take the resin at an interval of 2 hours prior to administration of HYPERCHOL. The combined use of Fibrate and derivates and HMG-CoA reductase inhibitors may produce myopathy. So far there is no proof of clinical interactions of Fenofibrate with other drugs. As with other fibrate derivatives, it is advisable to monitor the concurrent use with oral hypoglycemic agents.
Sign Out
